Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial. 1993

E T Janson, and H L Kauppinen, and K Oberg
Department of Internal Medicine, University Hospital, Uppsala, Sweden.

A phase I-II trial was initiated to investigate the effects of a combination of alpha- and gamma-interferon in 12 patients with malignant carcinoid tumors. All patients were treated with alpha-interferon at a dose of 5-10 MU, 3-5 times weekly for a median of 22 months and had stable or progressive disease. Gamma-interferon was added at a daily dose of 0.5 MU subcutaneously. After 3 months of treatment 4 patients showed progressive biochemical disease while 8 patients had continuous stable biochemical disease. The dose was escalated to 1 MU daily in 8 patients while 3 continued at lower dose levels. Gamma-interferon was withdrawn from one patient due to mental depression. At 6 months there was 1 partial response, 3 patients with progressive and 7 with stable disease. Half of the patients experienced increased fatigue during the study. Other adverse reactions were skin lesions and myalgia. The combination therapy demonstrated subjective improvement in half of the patients, but lacked antitumoral effects.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007414 Intestinal Neoplasms Tumors or cancer of the INTESTINES. Cancer of Intestines,Intestinal Cancer,Cancer of the Intestines,Intestines Cancer,Intestines Neoplasms,Neoplasms, Intestinal,Cancer, Intestinal,Cancer, Intestines,Cancers, Intestinal,Cancers, Intestines,Intestinal Cancers,Intestinal Neoplasm,Intestines Cancers,Intestines Neoplasm,Neoplasm, Intestinal,Neoplasm, Intestines,Neoplasms, Intestines
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008303 Malignant Carcinoid Syndrome A symptom complex associated with CARCINOID TUMOR and characterized by attacks of severe flushing of the skin, diarrheal watery stools, bronchoconstriction, sudden drops in blood pressure, edema, and ascites. The carcinoid tumors are usually located in the gastrointestinal tract and metastasize to the liver. Symptoms are caused by tumor secretion of serotonin, prostaglandins, and other biologically active substances. Cardiac manifestations constitute CARCINOID HEART DISEASE. (Dorland, 27th ed; Stedman, 25th ed) Carcinoid Syndrome, Malignant,Carcinoid Syndromes, Malignant,Malignant Carcinoid Syndromes,Syndrome, Malignant Carcinoid,Syndromes, Malignant Carcinoid
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002276 Carcinoid Tumor A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182) Argentaffinoma,Carcinoid,Carcinoid, Goblet Cell,Argentaffinomas,Carcinoid Tumors,Carcinoids,Carcinoids, Goblet Cell,Goblet Cell Carcinoid,Goblet Cell Carcinoids,Tumor, Carcinoid,Tumors, Carcinoid
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E T Janson, and H L Kauppinen, and K Oberg
August 1991, Annals of internal medicine,
E T Janson, and H L Kauppinen, and K Oberg
January 1994, World journal of surgery,
E T Janson, and H L Kauppinen, and K Oberg
January 2004, Investigational new drugs,
E T Janson, and H L Kauppinen, and K Oberg
January 1992, Anticancer research,
E T Janson, and H L Kauppinen, and K Oberg
September 1992, Annals of oncology : official journal of the European Society for Medical Oncology,
E T Janson, and H L Kauppinen, and K Oberg
December 1987, Cancer treatment reports,
E T Janson, and H L Kauppinen, and K Oberg
October 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E T Janson, and H L Kauppinen, and K Oberg
August 1986, International journal of radiation oncology, biology, physics,
E T Janson, and H L Kauppinen, and K Oberg
January 1988, Nihon Gan Chiryo Gakkai shi,
Copied contents to your clipboard!